RedHill Biopharma Ltd. (RDHL) said the U. S. Patent and Trademark Office was not in the process of being able to improve the government. The U. S. Department of Agriculture and Drug Administration has granted a new use patent that protects the management of opaganib for the inhibition of a disease caused by coronavirus in a subgroup of the patient population requiring a stimulated or higher fraction of oxygen. 60% of the initial FiO2.
The new patent, expiring in 2041, titled “Sphingosine kinase 2 inhibitor for the treatment of coronavirus infection in patients with moderately severe pneumonia,” protects the effects of a global Phase 2/3 post-hoc investigation in hospitalized patients with COVID-19 pneumonia.
Analysis of 251 test participants requiring FiO2 of up to 60% at baseline (54% of test participants) showed that treatment with oral opaganib resulted in 62% relief in mortality, advanced ambient air exposure, and median time to hospital discharge outcomes, and reduced the likelihood of intubation and mechanical ventilation in this gigantic organization of hospitalized COVID-19 patients. and with severe moderation.
For more information on fitness, rttnews. com